Addex Therapeutics spin─out company, Neurosterix completes phase 1 clinical studies of NTX─253 for schizophrenia
Addex Therapeutics, a clinical─stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced that its spin─out company,
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →